MedTrace Logo

Impact of Long-term Protease Inhibitors in Patients Living With HIV on the Incidence of COVID-19 ( COVIP )

NCT04357639 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1040

Last updated 2021-08-02

No results posted yet for this study

Summary

This is a prospective multicenter cohort study. The question arises as to whether treatment with protease inhibitors (PIs) could have a preventive role for COVID-19 infection, especially since patients living with HIV (PLWHIV) have not been described as more at risk of developing COVID-19 infection.

The aim of our study will therefore be to assess the impact of long-term protease inhibitors in PLWHIV on the incidence of COVID-19.

Conditions

  • HIV Patients

Interventions

OTHER

No intervention

No intervention: Usual care for nasopharyngeal sampling and blood sampling for COVID-19 detection

Sponsors & Collaborators

  • Centre Hospitalier Intercommunal Villeneuve St Georges

    collaborator UNKNOWN

  • Centre Hospitalier Intercommunal Creteil

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-28
Primary Completion
2021-01-31
Completion
2021-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04357639 on ClinicalTrials.gov